|
|||||
|
|
The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor. |
|
| Authors: | P Prasit Z Wang C Brideau C C Chan S Charleson W Cromlish D Ethier J F Evans A W Ford-Hutchinson J Y Gauthier R Gordon J Guay M Gresser S Kargman B Kennedy Y Leblanc S Léger J Mancini G P O'Neill M Ouellet M D Percival H Perrier D Riendeau I Rodger R Zamboni |
| Institution: | Merck Frosst Centre for Therapeutic Research, Pointe Claire-Dorval, Québec, Canada. |
| Abstract: | The development of a COX-2 inhibitor rofecoxib (MK 966, Vioxx) is described. It is essentially equipotent to indomethacin both in vitro and in vivo but without the ulcerogenic side effect due to COX-1 inhibition. |
| Keywords: | |